Carfilzomib and Dexamethasone for Treating Patients with Relapsed or Refractory Myeloma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase IITreatment18 and overS1304
NCI-2013-00796, PS1304_A07PAMDREVW01, SWOG-S1304, NCT01903811

Trial Description

Summary

This randomized phase II trial compares how well two different doses of carfilzomib work when given with dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement or has not responded to treatment. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib together with dexamethasone may kill more cancer cells. It is not yet known whether a higher or lower dose of carfilzomib works better when given with dexamethasone.

Further Study Information

PRIMARY OBJECTIVES:

I. To evaluate and compare progression free survival (PFS) of two different doses of carfilzomib with dexamethasone in multiple myeloma (MM) patients with relapsed and/or refractory disease.

SECONDARY OBJECTIVES:

I. To evaluate and compare response rates (RR) for each arm.

II. To evaluate response rates (RR) for patients that relapse on low dose carfilzomib and subsequently cross-over to high dose carfilzomib.

III. To evaluate the safety of this combination for this patient population.

IV. To evaluate overall survival (OS).

TERTIARY OBJECTIVES:

I. To explore the molecular variability in MM cells obtained from extramedullary bone marrow relapse sites.

II. To explore the role of positron emission tomography (PET) scanning in assessing disease burden and as a tool to assess treatment response.

III. To explore changes in left ventricular ejection fraction (LVEF) in patients with relapsed or refractory multiple myeloma treated with low dose carfilzomib or high dose carfilzomib plus dexamethasone.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive dexamethasone intravenously (IV) and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. Patients with progression cross-over to Arm II.

ARM II: Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16.

Note that for the first course of treatment on both arms carfilzomib is given at a reduced rate to assess toxicity.

In both arms, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 3 years from initial registration.

Eligibility Criteria

Inclusion Criteria:

Patients must have begun cycle 2 (carfilzomib – 27 mg/m^2) and must not have received any dose reduction for toxicity in the last cycle of treatment, immediately preceding progression

Patient must have been eligible for and initially randomized to Arm 1 (low dose carfilzomib), begun cycle 2 of treatment, and progressed prior to completing 12 cycles of protocol therapy

Patients may have received palliative external beam radiation therapy (XRT) for local disease control with no curative intent. XRT must be completed at least 7 days prior to registration

Patients must have received at least one prior regimen of chemotherapy for symptomatic multiple myeloma; patients may not have more than six (6) previous regimens of therapy for the disease; prior chemotherapy must have been completed at least 21 days prior to registration; for study purposes, a regimen is defined as follows:

An anti-myeloma therapy used at the time of initial diagnosis or documented disease progression which is given with the intent to decrease disease burden

Any maintenance therapy used after an Induction should be considered part of that Induction regimen

Use of any agent or combination of agents more than once during the patient’s disease history for separate documented disease progressions will be counted as separate regimens (e.g., if a patient receives lenalidomide/bortezomib at initial diagnosis and achieves response, but then progresses and receives lenalidomide/bortezomib after progression, these count as 2 separate regimens)

In cases of allogeneic or autologous stem cell transplant, the entire induction + stem cell mobilization + conditioning + planned maintenance should be considered one regimen

Patients must have a confirmed diagnosis of symptomatic multiple myeloma and must be currently relapsed or refractory; all tests for establishing disease status must be completed within 28 days prior to registration and documented on the Baseline Tumor Assessment Form for Multiple Myeloma

Patients must have measurable disease within 28 days prior to registration

Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =< 3 x ULN

Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support within 14 days prior to registration

Patients must have Zubrod performance status 0-2

Patients must have undergone an electrocardiogram (EKG) within 28 days prior to registration

Patients must have recovered from all non-hematologic toxicities to =< grade 2 and from all hematologic toxicities to =< grade 3 prior to registration

Total bilirubin =< 1.5 x upper limit of normal (ULN)

Patients must not have > grade 2 neuropathy and/or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)

Platelets >= 50,000 cells/mm^3 for patients who have bone marrow plasmacytosis < 50% or >= 30,000 cells/mm^3 for patients who have bone marrow plasmacytosis of >= 50% within 14 days prior to registration

Patients must have baseline skeletal survey to document lytic lesions, osteopenia or compression fracture within 28 days prior to registration

Patients must be offered participation in specimen submission for translational medicine studies and banking; with patient consent, specimens must be submitted

Patients with known hepatitis B or hepatitis C infection must have viral load < 800,000 IU/L within 28 days prior to registration

Patients must have serum protein electrophoresis (SPEP) and kappa and lambda light chain testing performed within 14 days prior to registration in order to establish baseline measurements

No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years

As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system

At least 14 days and no more than 28 days must have elapsed between the last day of treatment on Arm 1 and registration to Arm 3

REGISTRATION STEP 1: INITIAL RANDOMIZATION

Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:

Cluster of differentiation (CD)4 cells >= 500/mm^3

Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART

No zidovudine or stavudine as part of cART

Patients who are HIV+ and do not meet all of these criteria are not eligible for this study

REGISTRATION STEP 2: CROSSOVER

Patients must not have ejection fraction decrease > 10% from baseline (as determined by ECHO) or other ejection fraction decrease accompanied by other clinical signs/symptoms of New York Heart Association (NYHA) class III or IV heart failure, measured within 28 days prior to registration; if any question exists regarding individual patient eligibility in this situation, contact the study chair for determination

Calculated or measured creatinine clearance >= 30 ml/min within 14 days prior to registration

Patients must have either echocardiogram (ECHO) with ejection fraction >= 45% within 28 days prior to registration

Patients may not have received any prior carfilzomib treatment

Patients must not be receiving any other concurrent therapy considered to be investigational; patients must not be planning to receive any radiotherapy (except localized radiation for palliative care); patients must not be planning to receive any concurrent chemotherapy, immunotherapy, radiotherapy or other treatment with curative intent

Patients must have baseline PET scan within 28 days prior to registration; note that images are submitted centrally for review

Patients with non-secretory MM or known primary amyloidosis are not eligible

Patients must not have clinically significant illness including uncontrolled, active infection requiring intravenous antibiotics, New York Heart Association (NYHA) class III or class IV heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or >= grade 3 cardiac arrhythmias

Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures

Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines

Patients must have complete history and physical examination within 28 days prior to registration

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

SWOG

  • National Cancer Institute
Sikander Ailawadhi, Principal Investigator

Trial Sites

U.S.A.

Arizona
Tucson

The University of Arizona Cancer Center-North Campus

Ravitharan Krishnadasan
Ph: 520-626-9008

Ravitharan Krishnadasan
Principal Investigator

The University of Arizona Medical Center-University Campus

Ravitharan Krishnadasan
Ph: 520-626-9008

Ravitharan Krishnadasan
Principal Investigator

California
Anaheim

Kaiser Permanente-Anaheim

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Antioch

Kaiser Permanente-Deer Valley Medical Center

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Auburn

Sutter Auburn Faith Hospital

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Sutter Cancer Centers Radiation Oncology Services-Auburn

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Baldwin Park

Kaiser Permanente Medical Group - Baldwin Park

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Bellflower

Kaiser Foundation Hospital

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Berkeley

Alta Bates Summit Medical Center-Herrick Campus

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Burlingame

Mills - Peninsula Hospitals

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Cameron Park

Sutter Cancer Centers Radiation Oncology Services-Cameron Park

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Concord

John Muir Medical Center-Concord Campus

Kasra Karamlou
Ph: 925-674-2580

Kasra Karamlou
Principal Investigator

Davis

Sutter Davis Hospital

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Fontana

Kaiser Permanente Hospital

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Fremont

Kaiser Permanente, Fremont

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Fresno

Kaiser Permanente

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Harbor City

Kaiser Permanente - Harbor City

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Irvine

Southern California Permanente Medical Group

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Los Angeles

Kaiser Permanente Los Angeles Medical Center

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Kaiser Permanente-West Los Angeles

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Los Angeles County-USC Medical Center

Kevin R. Kelly
Ph: 323-865-0451

Kevin R. Kelly
Principal Investigator

USC / Norris Comprehensive Cancer Center

Kevin R. Kelly
Ph: 323-865-0451

Kevin R. Kelly
Principal Investigator

Marysville

Fremont - Rideout Cancer Center

Joseph M. Tuscano
Ph: 916-734-3089

Joseph M. Tuscano
Principal Investigator

Modesto

Kaiser Permanente-Modesto

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Memorial Medical Center

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Mountain View

Palo Alto Medical Foundation-Camino Division

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Palo Alto Medical Foundation-Gynecologic Oncology

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Novato

Sutter Cancer Research Consortium

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Oakland

Kaiser Permanente-Oakland

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Orange

UC Irvine Health/Chao Family Comprehensive Cancer Center

Kanwarpal S. Kahlon
Ph: 877-827-8839
Email: ucstudy@uci.edu

Kanwarpal S. Kahlon
Principal Investigator

Palo Alto

Palo Alto Medical Foundation Health Care

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Panorama City

Kaiser Permanente - Panorama City

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Redwood City

Kaiser Permanente-Redwood City

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Richmond

Kaiser Permanente-Richmond

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Riverside

Kaiser Permanente Medical Center

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Roseville

Kaiser Permanente-Roseville

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Sutter Cancer Centers Radiation Oncology Services-Roseville

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Sutter Roseville Medical Center

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Sacramento

Kaiser Permanente - Sacramento

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Kaiser Permanente-South Sacramento

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Sutter General Hospital

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

University of California Davis Comprehensive Cancer Center

Joseph M. Tuscano
Ph: 916-734-3089

Joseph M. Tuscano
Principal Investigator

San Diego

Kaiser Permanente at San Diego

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Kaiser Permanente-San Diego Mission

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

San Francisco

California Pacific Medical Center-Pacific Campus

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Kaiser Permanente-San Francisco

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

San Jose

Kaiser Permanente-Santa Teresa-San Jose

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

San Leandro

Kaiser Permanente San Leandro

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

San Marcos

Kaiser Permanente Health Care

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

San Rafael

Kaiser Permanente-San Rafael

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Santa Clara

Kaiser Permanente Medical Center - Santa Clara

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Santa Cruz

Palo Alto Medical Foundation-Santa Cruz

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Santa Rosa

Kaiser Permanente-Santa Rosa

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Sutter Pacific Medical Foundation

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

South San Francisco

Kaiser Permanente-South San Francisco

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Stockton

Kaiser Permanente-Stockton

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Sunnyvale

Palo Atlo Medical Foundation-Sunnyvale

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Truckee

Tahoe Forest Cancer Center

Joseph M. Tuscano
Ph: 916-734-3089

Joseph M. Tuscano
Principal Investigator

Vacaville

Kaiser Permanente Medical Center-Vacaville

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Sutter Cancer Centers Radiation Oncology Services-Vacaville

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Vallejo

Kaiser Permanente-Vallejo

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Sutter Solano Medical Center/Cancer Center

Ari David Baron
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Ari David Baron
Principal Investigator

Walnut Creek

John Muir Medical Center-Walnut Creek

Kasra Karamlou
Ph: 925-674-2580

Kasra Karamlou
Principal Investigator

Kaiser Permanente-Walnut Creek

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Woodland Hills

Kaiser Permanente

Han A. Koh
Ph: 626-564-3455

Han A. Koh
Principal Investigator

Connecticut
Derby

The Center for Cancer Care at Griffin Hospital

Terri Lynn Parker
Ph: 203-785-5702

Terri Lynn Parker
Principal Investigator

Fairfield

Smilow Cancer Hospital Care Center-Fairfield

Terri Lynn Parker
Ph: 203-785-5702

Terri Lynn Parker
Principal Investigator

Guilford

Medical Oncology and Hematology Group PC-Guilford

Terri Lynn Parker
Ph: 203-785-5702

Terri Lynn Parker
Principal Investigator

Hartford

Saint Francis Hospital and Medical Center

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

New Haven

Yale University

Terri Lynn Parker
Ph: 203-785-5702

Terri Lynn Parker
Principal Investigator

North Haven

Yale-New Haven Hospital North Haven Medical Center

Terri Lynn Parker
Ph: 203-785-5702

Terri Lynn Parker
Principal Investigator

Orange

Smilow Cancer Hospital-Orange Care Center

Terri Lynn Parker
Ph: 203-785-5702

Terri Lynn Parker
Principal Investigator

Torrington

Charlotte Hungerford Hospital Center for Cancer Care

Terri Lynn Parker
Ph: 203-785-5702

Terri Lynn Parker
Principal Investigator

Trumbull

Smilow Cancer Hospital Care Center-Trumbull

Terri Lynn Parker
Ph: 203-785-5702

Terri Lynn Parker
Principal Investigator

Waterbury

Smilow Cancer Hospital at The Harold Leever Regional Cancer Center

Terri Lynn Parker
Ph: 203-785-5702

Terri Lynn Parker
Principal Investigator

Delaware
Lewes

Beebe Medical Center

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Newark

Christiana Care Health System-Christiana Hospital

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Christiana Gynecologic Oncology LLC

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Delaware Clinical and Laboratory Physicians PA

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Helen F Graham Cancer Center

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Medical Oncology Hematology Consultants PA

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Regional Hematology and Oncology PA

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Rehoboth Beach

Beebe Health Campus

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Seaford

Nanticoke Memorial Hospital

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Wilmington

Christiana Care Health System-Wilmington Hospital

Stephen Scott Grubbs
Ph: 302-733-6227

Stephen Scott Grubbs
Principal Investigator

Florida
Gainesville

University of Florida

Jan Suliman Moreb
Ph: 352-273-8675
Email: trials@cancer.ufl.edu

Jan Suliman Moreb
Principal Investigator

Jacksonville

Mayo Clinic in Florida

Ronald S. Go
Ph: 507-538-7623

Ronald S. Go
Principal Investigator

Georgia
Savannah

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

Ovidiu George Negrea
Ph: 912-350-8568

Ovidiu George Negrea
Principal Investigator

Hawaii
Aiea

Oncare Hawaii Inc-Pali Momi

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Pali Momi Medical Center

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Honolulu

Kaiser Permanente Moanalua Medical Center

Tatjana Kolevska
Ph: 626-564-3455

Tatjana Kolevska
Principal Investigator

Kuakini Medical Center

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Oncare Hawaii Inc-Kuakini

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Oncare Hawaii Inc-POB II

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

OnCare Hawaii-Liliha

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Queen's Medical Center

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Straub Clinic and Hospital

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

University of Hawaii Cancer Center

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Lihue

Wilcox Memorial Hospital and Kauai Medical Clinic

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Coeur D'Alene

Kootenai Medical Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Post Falls

Kootenai Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Sandpoint

Kootenai Cancer

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Illinois
Bloomington

Illinois CancerCare-Bloomington

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Saint Joseph Medical Center

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Canton

Illinois CancerCare-Canton

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Carbondale

Memorial Hospital of Carbondale

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carthage

Illinois CancerCare-Carthage

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Centralia

Centralia Oncology Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Danville

Carle on Vermilion

Wenqing Zhang
Ph: 800-446-5532

Wenqing Zhang
Principal Investigator

Decatur

Cancer Care Center of Decatur

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Effingham

Carle Physician Group-Effingham

Wenqing Zhang
Ph: 800-446-5532

Wenqing Zhang
Principal Investigator

Crossroads Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Eureka

Illinois CancerCare-Eureka

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Galesburg

Illinois CancerCare Galesburg

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Illinois CancerCare-Galesburg Cottage Plaza Office

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Hinsdale

Hinsdale Hematology Oncology Associates Incorporated

Elyse Cheryl Schneiderman
Ph: 630-654-1790
Email: info@hhoaltd.com

Elyse Cheryl Schneiderman
Principal Investigator

Kewanee

Illinois CancerCare-Kewanee Clinic

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Macomb

Illinois CancerCare-Macomb

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Mattoon

Carle Physician Group-Mattoon/Charleston

Wenqing Zhang
Ph: 800-446-5532

Wenqing Zhang
Principal Investigator

Maywood

Loyola University Medical Center

Tulio E. Rodriguez
Ph: 708-226-4357

Tulio E. Rodriguez
Principal Investigator

Moline

Garneau, Stewart C MD (UIA Investigator)

David Martens Spector
Ph: 309-779-4200

David Martens Spector
Principal Investigator

Spector, David MD (UIA Investigator)

David Martens Spector
Ph: 309-779-4200

David Martens Spector
Principal Investigator

Trinity Medical Center

David Martens Spector
Ph: 309-779-4200

David Martens Spector
Principal Investigator

Mount Vernon

Good Samaritan Regional Health Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Ottawa

Illinois CancerCare-Ottawa Clinic

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Pekin

Illinois CancerCare-Pekin

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Pekin Cancer Treatment Center

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Peoria

Illinois CancerCare-Peoria

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Methodist Medical Center of Illinois

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

OSF Saint Francis Medical Center

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Peru

Illinois CancerCare-Peru

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Princeton

Illinois CancerCare-Princeton

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Rockford

SwedishAmerican Regional Cancer Center/ACT

Harvey E. Einhorn
Ph: 779-696-9400
Email: cancercare@swedishamerican.org

Harvey E. Einhorn
Principal Investigator

Springfield

Memorial Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Swansea

Cancer Care Specialists of Illinois-Swansea

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Urbana

Carle Cancer Center

Wenqing Zhang
Ph: 800-446-5532

Wenqing Zhang
Principal Investigator

The Carle Foundation Hospital

Wenqing Zhang
Ph: 800-446-5532

Wenqing Zhang
Principal Investigator

Indiana
Richmond

Reid Hospital and Health Care Services

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Iowa
Ames

Mary Greeley Medical Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

McFarland Clinic PC-William R Bliss Cancer Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Bettendorf

Constantinou, Costas L MD (UIA Investigator)

David Martens Spector
Ph: 309-779-4200

David Martens Spector
Principal Investigator

Hematology Oncology Associates-Quad Cities

Shobha R. Chitneni
Ph: 563-355-7733
Email: kedaprile@rccqc.com

Shobha R. Chitneni
Principal Investigator

Boone

McFarland Clinic PC-Boone

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Davenport

Genesis Medical Center - East Campus

George Kovach
Ph: 800-446-6088
Email: werners@genesishealth.com

George Kovach
Principal Investigator

Des Moines

Iowa Lutheran Hospital

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Iowa Methodist Medical Center

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Iowa Oncology Research Association CCOP

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Medical Oncology and Hematology Associates-Des Moines

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Fort Dodge

McFarland Clinic PC-Trinity Cancer Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Jefferson

McFarland Clinic PC-Jefferson

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Marshalltown

McFarland Clinic PC-Marshalltown

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Sioux City

Siouxland Regional Cancer Center

Donald B. Wender
Ph: 712-252-0088

Donald B. Wender
Principal Investigator

West Des Moines

Methodist West Hospital

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Kansas
Chanute

Cancer Center of Kansas - Chanute

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Dodge City

Cancer Center of Kansas - Dodge City

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

El Dorado

Cancer Center of Kansas - El Dorado

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Fort Scott

Cancer Center of Kansas - Fort Scott

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Independence

Cancer Center of Kansas-Independence

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Kingman

Cancer Center of Kansas-Kingman

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Lawrence

Lawrence Memorial Hospital

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Liberal

Cancer Center of Kansas-Liberal

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Newton

Cancer Center of Kansas - Newton

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Parsons

Cancer Center of Kansas - Parsons

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Pratt

Cancer Center of Kansas - Pratt

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Salina

Cancer Center of Kansas - Salina

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Wellington

Cancer Center of Kansas - Wellington

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Wichita

Associates In Womens Health

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Cancer Center of Kansas - Main Office

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Cancer Center of Kansas-Wichita Medical Arts Tower

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Via Christi Regional Medical Center

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Winfield

Cancer Center of Kansas - Winfield

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Kentucky
Crestview Hills

Oncology Hematology Care Inc-Crestview

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Louisiana
New Orleans

Tulane University Health Sciences Center

Hana F. Safah
Ph: 504-988-6121

Hana F. Safah
Principal Investigator

Maine
Augusta

Harold Alfond Center for Cancer Care

Thomas H. Openshaw
Ph: 207-973-4274

Thomas H. Openshaw
Principal Investigator

Bangor

Eastern Maine Medical Center

Thomas H. Openshaw
Ph: 207-973-4274

Thomas H. Openshaw
Principal Investigator

Rockport

Penobscot Bay Medical Center

Thomas H. Openshaw
Ph: 207-973-4274

Thomas H. Openshaw
Principal Investigator

Maryland
Salisbury

Peninsula Regional Medical Center

Paul E. Zorsky
Ph: 410-543-7017
Email: sandra.heineken@peninsula.org

Paul E. Zorsky
Principal Investigator

Massachusetts
Beverly

Beverly Hospital

Angus P. McIntyre
Ph: 978-283-4000ext559

Angus P. McIntyre
Principal Investigator

Boston

Boston Medical Center

Vaishali Sanchorawala
Ph: 617-638-8265

Vaishali Sanchorawala
Principal Investigator

Burlington

Lahey Hospital and Medical Center

Tarun Kewalramani
Ph: 781-744-8027

Tarun Kewalramani
Principal Investigator

Gloucester

Addison Gilbert Hospital

Angus P. McIntyre
Ph: 978-283-4000ext559

Angus P. McIntyre
Principal Investigator

Michigan
Adrian

Hickman Cancer Center

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Ann Arbor

Saint Joseph Mercy Hospital

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Dearborn

Oakwood Hospital and Medical Center

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Detroit

Saint John Hospital and Medical Center

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Wayne State University/Karmanos Cancer Institute

Jeffrey Allan Zonder
Ph: 313-576-9363

Jeffrey Allan Zonder
Principal Investigator

Escanaba

Green Bay Oncology - Escanaba

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Farmington Hills

Weisberg Cancer Treatment Center

Jeffrey Allan Zonder
Ph: 313-576-9363

Jeffrey Allan Zonder
Principal Investigator

Flint

Genesys Hurley Cancer Institute

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Hurley Medical Center

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Iron Mountain

Green Bay Oncology - Iron Mountain

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Jackson

Allegiance Health

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Kalamazoo

Borgess Medical Center

Raymond Sterling Lord
Ph: 269-373-7458

Raymond Sterling Lord
Principal Investigator

Bronson Methodist Hospital

Raymond Sterling Lord
Ph: 269-373-7458

Raymond Sterling Lord
Principal Investigator

West Michigan Cancer Center

Raymond Sterling Lord
Ph: 269-373-7458

Raymond Sterling Lord
Principal Investigator

Lansing

Sparrow Hospital

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Livonia

Saint Mary Mercy Hospital

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Monroe

Toledo Clinic Cancer Centers-Monroe

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Port Huron

Saint Joseph Mercy Port Huron

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Saginaw

Saint Mary's of Michigan

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Southfield

Providence Hospital

Howard R. Terebelo
Ph: 248-849-5337
Email: jaswinder.grewal@stjohn.org

Howard R. Terebelo
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Minnesota
Bemidji

Sanford Clinic North-Bemidgi

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Burnsville

Fairview Ridges Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Coon Rapids

Mercy Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Edina

Fairview-Southdale Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Fridley

Unity Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Hutchinson

Hutchinson Area Health Care

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Maplewood

Minnesota Oncology Hematology PA-Maplewood

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Saint John's Hospital - Healtheast

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Minneapolis

Abbott-Northwestern Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Health Partners Inc

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Hennepin County Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

New Ulm

New Ulm Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Robbinsdale

North Memorial Medical Health Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Rochester

Mayo Clinic

Ronald S. Go
Ph: 507-538-7623

Ronald S. Go
Principal Investigator

Saint Louis Park

Park Nicollet Clinic - Saint Louis Park

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Saint Paul

Regions Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

United Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Shakopee

Saint Francis Regional Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Stillwater

Lakeview Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Waconia

Ridgeview Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Willmar

Rice Memorial Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Woodbury

Minnesota Oncology and Hematology PA-Woodbury

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Mississippi
Jackson

University of Mississippi Medical Center

Tondre T. Buck
Ph: 601-815-6700

Tondre T. Buck
Principal Investigator

Missouri
Bolivar

Central Care Cancer Center-Carrie J Babb Cancer Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Bonne Terre

Parkland Health Center-Bonne Terre

Bryan A. Faller
Ph: 800-392-0936

Bryan A. Faller
Principal Investigator

Branson

CoxHealth Cancer Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Cape Girardeau

Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southeast Cancer Center

Alan P. Lyss
Ph: 800-392-0936

Alan P. Lyss
Principal Investigator

Chesterfield

Saint Luke's Hospital

Donald F. Busiek
Ph: 314-205-6936

Donald F. Busiek
Principal Investigator

Jefferson City

Capital Region Medical Center-Goldschmidt Cancer Center

Alan P. Lyss
Ph: 800-392-0936

Alan P. Lyss
Principal Investigator

Joplin

Freeman Health System

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Rolla

Phelps County Regional Medical Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint John's Clinic-Rolla-Cancer and Hematology

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint Louis

Mercy Hospital Saint Louis

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Missouri Baptist Medical Center

Alan P. Lyss
Ph: 800-392-0936

Alan P. Lyss
Principal Investigator

Saint Louis Cancer and Breast Institute-South City

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Sainte Genevieve

Sainte Genevieve County Memorial Hospital

Bryan A. Faller
Ph: 800-392-0936

Bryan A. Faller
Principal Investigator

Springfield

CoxHealth South Hospital

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Mercy Hospital Springfield

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Sullivan

Missouri Baptist Sullivan Hospital

Bryan A. Faller
Ph: 800-392-0936

Bryan A. Faller
Principal Investigator

Sunset Hills

Missouri Baptist Outpatient Center-Sunset Hills

Bryan A. Faller
Ph: 800-392-0936

Bryan A. Faller
Principal Investigator

Montana
Billings

Billings Clinic Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Montana Cancer Consortium CCOP

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Saint Vincent Healthcare

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Bozeman

Bozeman Deaconess Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Butte

Saint James Community Hospital and Cancer Treatment Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Great Falls

Benefis Healthcare- Sletten Cancer Institute

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Helena

Saint Peter's Community Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Kalispell

Kalispell Regional Medical Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Missoula

Community Medical Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Saint Patrick Hospital - Community Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Nevada
Henderson

21st Century Oncology - Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Cancer and Blood Specialists-Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada - Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada-Southeast Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Las Vegas Cancer Center-Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Las Vegas

21st Century Oncology

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

21st Century Oncology - Fort Apache

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

21st Century Oncology - Vegas Tenaya

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Cancer and Blood Specialists-Fort Apache

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Cancer and Blood Specialists-Shadow

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Cancer and Blood Specialists-Tenaya

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Cancer Therapy and Integrative Medicine

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada - Central Valley

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada - Northwest

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada-Summerlin

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

HealthCare Partners Medical Group Oncology/Hematology-San Martin

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

HealthCare Partners Medical Group Oncology/Hematology-Tenaya

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Las Vegas Cancer Center-Medical Center

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Nevada Cancer Research Foundation CCOP

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Radiation Oncology Centers of Nevada Central

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Radiation Oncology Centers of Nevada Southeast

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

University Medical Center of Southern Nevada

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

New Jersey
Vineland

Inspira Medical Center Vineland

Tami Lee Bach
Ph: 856-641-7933

Tami Lee Bach
Principal Investigator

Woodbury

Inspira Medical Center Woodbury

Carl J. Minniti
Ph: 856-641-7933

Carl J. Minniti
Principal Investigator

New York
Middletown

Orange Regional Medical Center

Jeffrey M. Stewart
Ph: 845-342-7609

Jeffrey M. Stewart
Principal Investigator

North Carolina
Asheboro

Randolph Hospital

James Mitchell Granfortuna
Ph: 336-832-0821

James Mitchell Granfortuna
Principal Investigator

Burlington

Cone Health Cancer Center at Alamance Regional

James Mitchell Granfortuna
Ph: 336-832-0821

James Mitchell Granfortuna
Principal Investigator

Chapel Hill

University of North Carolina at Chapel Hill

Peter Michael Voorhees
Ph: 877-668-0683
Email: cancerclinicaltrials@med.unc.edu

Peter Michael Voorhees
Principal Investigator

Clinton

Southeastern Medical Oncology Center-Clinton

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Goldsboro

Southeastern Medical Oncology Center-Goldsboro

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Wayne Memorial Hospital

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Greensboro

Cone Health Cancer Center

James Mitchell Granfortuna
Ph: 336-832-0821

James Mitchell Granfortuna
Principal Investigator

Hendersonville

Hendersonville Hematology and Oncology at Pardee

James Earl Radford
Ph: 828-696-4716

James Earl Radford
Principal Investigator

Margaret R Pardee Memorial Hospital

James Earl Radford
Ph: 828-696-4716

James Earl Radford
Principal Investigator

Jacksonville

Southeastern Medical Oncology Center-Jacksonville

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Kinston

Kinston Medical Specialists PA

Peter Robins Watson
Ph: 252-559-2200

Peter Robins Watson
Principal Investigator

Mebane

Cone Heath Cancer Center at Mebane

James Mitchell Granfortuna
Ph: 336-832-0821

James Mitchell Granfortuna
Principal Investigator

Reidsville

Annie Penn Memorial Hospital

James Mitchell Granfortuna
Ph: 336-832-0821

James Mitchell Granfortuna
Principal Investigator

Statesville

Iredell Memorial Hospital

Ruby Ann Grimm
Ph: 704-873-5661

Ruby Ann Grimm
Principal Investigator

Wilson

Southeastern Medical Oncology Center-Wilson

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Winston-Salem

Wake Forest University Health Sciences

Rakhee Vaidya
Ph: 336-713-6771

Rakhee Vaidya
Principal Investigator

North Dakota
Bismarck

Sanford Bismarck Medical Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Fargo

Roger Maris Cancer Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Sanford Clinic North-Fargo

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Sanford Medical Center-Fargo

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Ohio
Belpre

Strecker Cancer Center-Belpre

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Canton

Aultman Health Foundation

James A. Schmotzer
Ph: 330-363-6891

James A. Schmotzer
Principal Investigator

Centerville

Miami Valley Hospital South

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Chillicothe

Adena Regional Medical Center

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Cincinnati

Oncology Hematology Care Inc - Anderson

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc - Kenwood

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc-Blue Ash

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc-Eden Park

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oncology Hematology Care Inc-Mercy West

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Columbus

Columbus Oncology and Hematology Associates Inc

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Doctors Hospital

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Grant Medical Center

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Mount Carmel Health Center West

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Riverside Methodist Hospital

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

The Mark H Zangmeister Center

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Dayton

Good Samaritan Hospital - Dayton

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Miami Valley Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Samaritan North Health Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Delaware

Delaware Health Center-Grady Cancer Center

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Delaware Radiation Oncology

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Grady Memorial Hospital

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Fairfield

Oncology Hematology Care Inc-Healthplex

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Findlay

Blanchard Valley Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Franklin

Atrium Medical Center-Middletown Regional Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Greenville

Wayne Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Kettering

Kettering Medical Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Lancaster

Fairfield Medical Center

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Marietta

Marietta Memorial Hospital

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Maumee

Toledo Clinic Cancer Centers-Maumee

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Toledo Radiation Oncology at Northwest Ohio Onocolgy Center

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Mount Vernon

Knox Community Hospital

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Newark

Licking Memorial Hospital

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Newark Radiation Oncology

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Oregon

Saint Charles Hospital

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Portsmouth

Southern Ohio Medical Center

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Springfield

Springfield Regional Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Sylvania

Flower Hospital

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Toledo

Mercy Saint Anne Hospital

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Toledo Clinic Cancer Centers-Toledo

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Toledo Community Hospital Oncology Program CCOP

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

University of Toledo

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Troy

Upper Valley Medical Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Westerville

Saint Ann's Hospital

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Wright-Patterson Afb

Wright-Patterson Medical Center

Roger Allen Wood
Ph: 937-257-1398

Roger Allen Wood
Principal Investigator

Zanesville

Genesis HealthCare System

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center

George B. Selby
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

George B. Selby
Principal Investigator

Pennsylvania
Bryn Mawr

Bryn Mawr Hospital

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

Danville

Geisinger Medical Center

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Hazleton

Geisinger Medical Center-Cancer Center Hazleton

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Lewisburg

Geisinger Medical Oncology at Evangelical Community Hospital

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Lewistown

Lewistown Hospital

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Media

Riddle Memorial Hospital

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

Paoli

Paoli Memorial Hospital

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

Philadelphia

University of Pennsylvania/Abramson Cancer Center

Adam David Cohen
Ph: 800-474-9892

Adam David Cohen
Principal Investigator

Pottsville

Geisinger Medical Oncology-Pottsville

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Reading

Saint Joseph Medical Center

Marc A. Rovito
Ph: 610-378-2336
Email: danielward2@catholichealth.net

Marc A. Rovito
Principal Investigator

Sellersville

Grand View Hospital

Anthony J. Magdalinski
Ph: 215-453-4162
Email: PParsons@gvh.org

Anthony J. Magdalinski
Principal Investigator

State College

Geisinger Medical Group

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

West Reading

Reading Hospital

Terrence Paul Cescon
Ph: 610-988-9323

Terrence Paul Cescon
Principal Investigator

Wilkes-Barre

Geisinger Wyoming Valley/Henry Cancer Center

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Wynnewood

Lankenau Medical Center

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

South Carolina
Anderson

AnMed Health Cancer Center

John Eric Doster
Ph: 864-512-1000

John Eric Doster
Principal Investigator

Florence

McLeod Regional Medical Center

Rajesh Bajaj
Ph: 843-679-7256

Rajesh Bajaj
Principal Investigator

South Dakota
Rapid City

Rapid City Regional Hospital

Joshua Cole Lukenbill
Ph: 605-716-3982
Email: research@rcrh.org

Joshua Cole Lukenbill
Principal Investigator

Sioux Falls

Sanford Cancer Center-Oncology Clinic

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Sanford USD Medical Center - Sioux Falls

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Texas
Houston

M D Anderson Cancer Center

Robert Zygmunt Orlowski
Ph: 713-792-3245

Robert Zygmunt Orlowski
Principal Investigator

Washington
Seattle

Virginia Mason Medical Center

Prakash Vishnu
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Prakash Vishnu
Principal Investigator

Wisconsin
Burlington

Aurora Cancer Care-Burlington

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Chippewa Falls

Marshfield Clinic-Chippewa Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Eau Claire

Marshfield Clinic Cancer Center at Sacred Heart

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Sacred Heart Hospital

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Elkhorn

Aurora Cancer Care-Southern Lakes

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Fond Du Lac

Aurora Health Center-Fond du Lac

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Grafton

Aurora Cancer Care-Grafton

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Green Bay

Aurora BayCare Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Green Bay Oncology at Saint Vincent Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Green Bay Oncology Limited at Saint Mary's Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Saint Mary's Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Saint Vincent Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Janesville

Mercy Health System

Emily Gray Robinson
Ph: 800-928-1103

Emily Gray Robinson
Principal Investigator

Kenosha

Aurora Cancer Care-Kenosha South

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Manitowoc

Holy Family Memorial Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Marinette

Bay Area Medical Center

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Vince Lombardi Cancer Clinic-Marinette

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Marshfield

Marshfield Clinic

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Saint Joseph's Hospital

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Menomonee Falls

Aurora Advanced Healthcare Inc-Menomonee Falls

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Milwaukee

Aurora Cancer Care-Milwaukee

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Aurora Cancer Care-Milwaukee South

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Aurora Saint Luke's Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Aurora Sinai Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Minocqua

Marshfield Clinic-Minocqua Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Mukwonago

D N Greenwald Center

Timothy Robert Wassenaar
Ph: 262-928-7878

Timothy Robert Wassenaar
Principal Investigator

New Richmond

Cancer Center of Western Wisconsin

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Oconomowoc

Oconomowoc Memorial Hospital-ProHealth Care Inc

Timothy Robert Wassenaar
Ph: 262-928-7878

Timothy Robert Wassenaar
Principal Investigator

Oconto Falls

Green Bay Oncology - Oconto Falls

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Oshkosh

Vince Lombardi Cancer Clinic - Oshkosh

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Racine

Aurora Cancer Care-Racine

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Rhinelander

Marshfield Clinic at James Beck Cancer Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Saint Mary's Hospital

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Rice Lake

Lakeview Medical Center-Marshfield Clinic

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Marshfield Clinic-Rice Lake Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Sheboygan

Saint Nicholas Hospital

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Vince Lombardi Cancer Clinic-Sheboygan

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Stevens Point

Marshfield Clinic Cancer Care at Saint Michael's Hospital

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Saint Michael's Hospital

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Sturgeon Bay

Green Bay Oncology - Sturgeon Bay

Matthew L. Ryan
Ph: 800-432-6049

Matthew L. Ryan
Principal Investigator

Summit

Aurora Medical Center in Summit

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Two Rivers

Vince Lombardi Cancer Clinic

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Waukesha

Aurora Cancer Care-Waukesha

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Waukesha Memorial Hospital

Timothy Robert Wassenaar
Ph: 262-928-7878

Timothy Robert Wassenaar
Principal Investigator

Wausau

Marshfield Clinic-Wausau Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Wauwatosa

Aurora Cancer Care-Milwaukee West

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

West Allis

Aurora West Allis Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Weston

Marshfield Clinic - Weston Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Saint Clare's Hospital

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Wisconsin Rapids

Marshfield Clinic - Wisconsin Rapids Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Wyoming
Cody

Big Horn Basin Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Billings Clinic-Cody

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Sheridan

Welch Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01903811

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.